These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 36926234)

  • 1. Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy.
    Zhang CY; Liu S; Yang M
    World J Hepatol; 2023 Feb; 15(2):180-200. PubMed ID: 36926234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
    Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
    Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
    Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
    Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma.
    Yu Q; Wu L; Ji J; Feng J; Dai W; Li J; Wu J; Guo C
    J Hepatocell Carcinoma; 2020; 7():271-288. PubMed ID: 33150145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis: An observational study.
    Marot A; Henrion J; Knebel JF; Moreno C; Deltenre P
    PLoS One; 2017; 12(10):e0186715. PubMed ID: 29077714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
    Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
    Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etiological Patterns, Liver Fibrosis Stages and Prescribing Patterns of Hepato-Protective Agents in Indian Patients with Chronic Liver Disease.
    Choudhuri G; Chaudhari S; Pawar D; Roy DS
    J Assoc Physicians India; 2018 Dec; 66(12):58-63. PubMed ID: 31315327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of alcoholic liver disease: role of oxidative metabolism.
    Ceni E; Mello T; Galli A
    World J Gastroenterol; 2014 Dec; 20(47):17756-72. PubMed ID: 25548474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD).
    Chen Q; Wang T; Li J; Wang S; Qiu F; Yu H; Zhang Y; Wang T
    Nutrients; 2017 Jan; 9(2):. PubMed ID: 28146130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).
    Choudhary NS; Duseja A
    Transl Gastroenterol Hepatol; 2021; 6():2. PubMed ID: 33409397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C.
    Golabi P; Paik JM; Eberly K; de Avila L; Alqahtani SA; Younossi ZM
    Ann Hepatol; 2022; 27(1):100556. PubMed ID: 34800721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of farnesoid X receptor and bile acids in alcoholic liver disease.
    Manley S; Ding W
    Acta Pharm Sin B; 2015 Mar; 5(2):158-67. PubMed ID: 26579442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment.
    Che W; Zhao M; Li X; Li C; Cho WC; Yu S
    Front Endocrinol (Lausanne); 2022; 13():1002916. PubMed ID: 36523601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches.
    Xu D; Xu M; Jeong S; Qian Y; Wu H; Xia Q; Kong X
    Front Pharmacol; 2018; 9():1428. PubMed ID: 30670963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
    Ezhilarasan D; Lakshmi T
    Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic liver disease and oxidative stress - a narrative review.
    Seen S
    Expert Rev Gastroenterol Hepatol; 2021 Sep; 15(9):1021-1035. PubMed ID: 34176419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.